Infectious Disease
Six-Month Strategy Holds Up in Rifampicin-Resistant TB
A South African randomized trial supports six-month treatment for eligible people with rifampicin-resistant tuberculosis, although safety, mortality, and US applicability require careful review.
Rayan Salih · August 24, 2026 · 7 min